Why did Ultragenyx’s Angelman setback put the focus back on discipline?

Ultragenyx’s recent FDA approval for Genglycos had boosted momentum, but that was undercut by a damaging phase 3 flop in Angelman syndrome and plans for significant expense reductions. The combination shifts attention from growth hopes to execution, portfolio prioritization, and whether tighter spending reflects prudent discipline or a defensive reset.